Compare Adaptive Biotechnologies Corp (ADPT) vs Dropbox Inc (DBX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Dropbox Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.69 (market cap $4.05B), while Dropbox Inc trades at $33.51 (market cap $7.52B). The key difference: Dropbox Inc is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Dropbox Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | DBX | |
|---|---|---|
Market Cap | $4.05B | $7.52B |
Sector | Health | Technology |
52-Week High | $25.45 | $35.00 |
52-Week Low | $12.30 | $22.06 |
Enterprise Value | $4.12B | $10.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
Dropbox (DBX) trades at $34.81, up 0.78% today, with a bullish technical signal and consistent earnings beats. The company reported Q2 2026 EPS of $0.75, exceeding estimates, and raised its full-year outlook. Revenue remains stable at $2.5B, with strong gross margins of 79.72%. However, negative shareholder equity and high debt levels pose financial risks.
The outlook is mixed: strong profitability and AI-driven growth support upside, but elevated leverage and competitive pressures warrant caution. Analyst sentiment is divided, with 37.5% recommending Buy. Key risks include execution challenges and market volatility. The stock's trajectory hinges on sustaining core business momentum amid macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →
